-

Veracyte to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences.

  • Raymond James 46th Annual Institutional Investors Conference – Orlando, FL
    Presentation on March 5th at 9:50 a.m. Eastern Time
  • Leerink Partners Global Healthcare Conference – Miami, FL
    Fireside Chat on March 11th at 8:40 a.m. Eastern Time

Live audio webcasts of the company’s presentations will be available by visiting Veracyte’s website at http://investor.veracyte.com/events-presentations. Replays of the webcasts will be available for 90 days after each live presentation broadcast.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com or follow us on LinkedIn or X (Twitter).

Contacts

Investors:
Shayla Gorman
investors@veracyte.com
(619) 393-1545

Media:
Tracy Morris
media@veracyte.com
(650) 380-4413

Veracyte, Inc.

NASDAQ:VCYT

Release Versions

Contacts

Investors:
Shayla Gorman
investors@veracyte.com
(619) 393-1545

Media:
Tracy Morris
media@veracyte.com
(650) 380-4413

More News From Veracyte, Inc.

Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the first quarter of 2025 after the close of market on Wednesday, May 7, 2025. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company’s website and will...

New Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--New Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer....

Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces 8 Abstracts Highlighting Performance and Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25...
Back to Newsroom